CagriSema: A Fixed-Dose Cagrilintide–Semaglutide Combination

Research summary. CagriSema is a fixed-dose combination of two long-acting peptide hormones developed by Novo Nordisk: cagrilintide (a long-acting amylin analogue) and semaglutide (a long-acting GLP-1 receptor agonist). The combination engages two anatomically and pharmacologically distinct appetite-regulating circuits in a single weekly subcutaneous dose, with the goal of producing greater weight loss and metabolic benefit than either component alone.

Composition

• Component 1: Cagrilintide (AM833) — long-acting amylin / calcitonin-receptor co-agonist
• Component 2: Semaglutide — long-acting glucagon-like peptide-1 receptor agonist
• Format: Fixed-dose combination, weekly subcutaneous administration
• Development code: Often referred to in the literature simply as "CagriSema" or by the combination of the component development names

The two peptides are chemically distinct molecules, each independently engineered with C18 fatty-acid acylation chains for albumin binding and extended half-life. The combination is co-formulated rather than chemically conjugated.

Pharmacological rationale

CagriSema is a deliberate exercise in complementary mechanism layering. The two components engage distinct, non-overlapping pathways that converge on appetite suppression and improved glucose handling:

• Semaglutide (GLP-1R agonism): Acts primarily via incretin signalling — enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and activating satiety circuits in the hypothalamus and brainstem via vagal afferents and direct CNS access.
• Cagrilintide (amylin/calcitonin receptor agonism): Acts primarily via the area postrema and adjacent circumventricular structures, modulating meal-related satiety and reducing post-prandial glucagon through a parallel but distinct mechanism.

Because the two pathways converge on overlapping behavioural and metabolic outputs through different receptors, mechanistic redundancy and downstream tachyphylaxis are reduced relative to single-agent dosing — a common rationale for multi-target peptide therapeutics in metabolic disease research.

Preclinical and clinical research highlights

Phase 1 combination study. The foundational human pharmacology paper for CagriSema (Enebo et al., 2021) reported a randomised, placebo-controlled trial of cagrilintide alone, semaglutide 2.4 mg alone, and the combination across 20 weeks in adults with overweight or obesity. The combination produced greater body-weight reduction than either monotherapy, with a tolerability profile broadly consistent with the individual components [1].

Phase 2 in type 2 diabetes. The Phase 2 study of CagriSema in adults with type 2 diabetes (reported in 2023) evaluated cagrilintide 2.4 mg + semaglutide 2.4 mg weekly versus the individual components. The combination produced HbA1c reductions and body-weight reductions exceeding those of either component alone, consistent with the additive-pathway hypothesis.

Phase 3 programme. Late-stage development is ongoing in the REDEFINE clinical-trial series for obesity and the REIMAGINE series for type 2 diabetes. Topline data from the REDEFINE-1 trial in obesity (reported late 2024) showed weight reduction in the range of approximately 22–23% over 68 weeks at the highest doses, accompanied by improvements in HbA1c, blood pressure, and lipid parameters in pre-specified subpopulations.

Comparative landscape. CagriSema is one entry in a broader landscape of multi-pathway metabolic peptides under active development, alongside tirzepatide (GIP/GLP-1 dual agonist, approved as Zepbound/Mounjaro), retatrutide (GIP/GLP-1/glucagon triple agonist, in late-stage trials), and survodutide (GLP-1/glucagon dual agonist).

Why complementary mechanisms matter

The conceptual progression from single-pathway agonists (e.g., liraglutide) to dual-pathway agonists (e.g., tirzepatide) to combination products such as CagriSema reflects an increasingly mechanistic approach to obesity pharmacology. Each layer of pathway engagement targets a different node of the appetite-regulation network, with the goal of recruiting more of the available physiological capacity for weight loss before metabolic adaptation (the so-called "weight-loss plateau") attenuates the response.

Current research status

CagriSema is an investigational fixed-dose combination in late-stage clinical development. It has not yet received marketing authorisation by the U.S. FDA, the EMA, or other major regulators at the time of writing. Reported Phase 3 results are encouraging but do not constitute regulatory approval, and definitive safety, efficacy, and labelling decisions await regulatory review.

Key takeaways for researchers

• CagriSema is a fixed-dose combination of cagrilintide (amylin analogue) and semaglutide (GLP-1 receptor agonist).
• The pharmacological logic combines two non-overlapping appetite-regulating pathways in a single weekly subcutaneous formulation.
• Phase 2 and Phase 3 data show body-weight reductions exceeding those reported for semaglutide alone in comparable populations.
• CagriSema is not approved as a marketed therapeutic at present.

References

1. Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. The Lancet. 2021;397(10286):1736–1748.

---

This article is provided for educational and research purposes only. CagriSema is an investigational fixed-dose combination peptide product. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving these peptides should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.